Clinical Trial Search

Primary: Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes — 5.55; -3.26 Incontinence Episodes

Primary: Detection of Medical Problems (by Number of Problems Reported by Computer Assisted History, That Were Not Reported by Physician Taken History) — 98 medical problems

Primary: Phase 1: Maximum Tolerated Dose (MTD) — 3.7 mg

Primary: Systemic, Pulmonary and Cerebral Blood Flow at Baseline and After Enalaprilat — 1.4; 1.8; 1.9; 1.9 l/min/m2 — p=0.09

Primary: Percentage of Participants With at Least One Hemoglobin Value Outside the Target Range — 97.9; 72.9; 33.7; 35.3 percentage of participants

Primary: Number of Children Diagnosed With ADHD With Structured Diagnostic Assessment — 34; 16 number of kids

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 3; 26; 0; 5 participants

Primary: Objective Tumor Response Rate — 28 percentage of participants

Primary: Evaluation of the Effect of B. Subtilis R0179 on Wellness Questionnaires for GI Distress — 0.5; 0.3; 0.6; 0.7 units on a scale

Primary: Functional Status — 42.2; 41.8; 40.6; 42.5 units on a scale

Primary: Percentage of Subjects Who Met Criteria for Remission Based on the Montgomery-Asberg Depression Rating Scale (MADRS) — 44; 29 percentage of participants

Primary: Clinical Benefit Rate — 54.5 percentage of participants

Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 16.7; 0; 50.0; 0 percentage of participants

Primary: AUSCAN Pain Change at 4 Weeks From Baseline — -9.0; -2.2 units on a scale — p=0.014

Primary: Participant Reduced Symptom Burden — -3.3; -2.8 units on a scale